A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Enrolling by invitation · Phase 3
Conditions studied: Warm Antibody Autoimmune Hemolytic Anemia
In brief
The primary objective of this study is: • To evaluate the long-term safety of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA).
Key facts
- Study ID
- NCT04138927
- Run by
- Rigel Pharmaceuticals
- People needed
- 90
- Starts
- 2019-10-30
- Expected to finish
- 2024-04-01
- Last updated by the study team
- 2022-03-17
Who can join
Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subject must be willing and able to give written informed consent by signing an IRB approved Informed Consent Form prior to undergoing any study-specific procedures.
- Subject must have completed all 24 weeks of participation in the study C-935788-057.
You may not qualify if…
- Any subject who discontinued participation in Study C-935788-057 prior to Week 24.
Where it is running
- University of Southern California - Janice and Robert Hall Clinical Trials Biospecimen Laboratory — Los Angeles, California, United States
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center — Torrance, California, United States
- Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia, United States
- John Hopkins Bayview Medical Center — Baltimore, Maryland, United States
- Massachusetts General Hospital — Boston, Massachusetts, United States
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
- American Oncology Network Vista Oncology Division — Olympia, Washington, United States
- University of Washington — Seattle, Washington, United States
- Princess Alexandra Hospital - Cancer Trials Unit — Brisbane, Queensland, Australia
- The Alfred Hospital — Melbourne, Victoria, Australia
- Hanusch-Krankenhaus — Vienna, Austria
- Universitätsklinik f. Innere Medizin I - Klin. Abt. f. Hämatologie u. Hämostaseologie — Vienna, Austria
- Vitebsk Regional Clinical Hospital — Vitebsk, Belarus
- Vitebsk Regional Clinical Oncology Dispensary — Vitebsk, Belarus
- AZ Nikolaas — Sint-Niklaas, Belgium
- University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD, Plovdiv, Clinic of Medical oncology — Pleven, Bulgaria
- University Multiprofile Hospital for Active Treatment Sv. Ivan Rilski EAD, Varna, Clinic of Clinical Haematology — Sofia, Bulgaria
- Specialized Hospital for Active Treatment of Hematological Disease EAD, — Sofia, Bulgaria
- Fakultni nemocnice Brno Interni hematologicka a onkologicka klinika — Brno, Czechia
- Fakultni nemocnice Ostrava Klinika hematoonkologie — Ostrava, Czechia
- CHU de Bordeaux - GH Sud- Hôpital Haut Lévêque Service Médecine Interne et Maladies Infectieuses — Pessac, France
- LTD Multiprofile Clinic Consilium Medulla — Tbilisi, Georgia
- M. Zodelava Hematology Centre, Tbilisi — Tbilisi, Georgia
- Universitätsklinikum Essen — Essen, Germany
- Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, UO Ematologia — Milan, Italy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.